Shanghai Henlius Biotech’s HLX22 Receives FDA Orphan-drug Designation

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.

Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius USA Inc., has received Orphan-drug Designation from the U.S. FDA for HLX22, a recombinant humanized anti-HER2 monoclonal antibody, for the treatment of gastric cancer. This designation is a significant milestone for the company, potentially enhancing its market position in the oncology sector. The global sales of HER2-targeting monoclonal antibody products are substantial, indicating a promising market for HLX22. The company is advancing clinical trials for HLX22 in multiple countries, which could lead to expanded treatment options for patients with HER2-positive cancers.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of monoclonal antibodies for the treatment of various cancers. The company is particularly involved in creating innovative therapies targeting HER2, a protein overexpressed in certain types of cancer, including gastric and breast cancer.

YTD Price Performance: 32.70%

Average Trading Volume: 1,300,141

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$17.09B

Learn more about 2696 stock on TipRanks’ Stock Analysis page.